BHV-1500 / Biohaven - LARVOL DELTA

Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology (PRNewswire) - "Next Generation ADC Platform:...The goal of its technology is to provide more stable and consistent drug antibody ratio (DAR) for use in oncology....(i) Initiate Phase 1 trial of BHV-1510 (Trop2) in 2Q 2024; (ii) File IND for BHV-1500 (next gen brentuximab ADC) in 2H 2024."

IND • New P1 trial • Oncology